The goal of this prospective cohort study is to investigate cardiac comorbidity in a random sample of approximately 1200 patients from a population of outpatients with rheumatoid arthritis and axial spondyloarthritis referred to collectively as inflammatory arthritis (IA). The main questions it aims to answer are: * Using conventional echocardiography, the investigators aim to determine the prevalence of overt and asymptomatic cardiac dysfunction in a large random sample of outpatients with IA. Cardiac dysfunction will be evaluated by echocardiography and cardiac biomarkers (NT-pro-BNP, hs-TNT and hs-CRP). * In patients without known heart disease: Using 2, 5 and 10 year follow-up, the investigators aim to examine if advanced echocardiography can be used to detect early signs of heart disease by investigating the clinical significance of adding deformation measures - alone and in combination with selected biomarkers - to conventional risk factors in the cardiac risk assessment of patients with IA Participants will undergo an echocardiographic examination in combination with a general health assessment including obtainment of cardiac biomarkers and a electrocardiogram. Using advanced echocardiography - Tissue Doppler Imaging, 2- dimensional speckle tracking echocardiography, 3D-echocardiography and 3-dimensional speckle tracking echocardiography - the investigators also aim to compare myocardial deformation parameters of patients with IA to a gender and age matched control group without IA from the Copenhagen City Heart Study.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Cardiovascular mortality
Timeframe: 2-year follow-up
Cardiovascular mortality
Timeframe: 5-year follow-up
Cardiovascular mortality
Timeframe: 10 year outcome
Admission with congestive heart failure
Timeframe: 2-year follow-up
Admission with congestive heart failure
Timeframe: 5-year follow-up
Admission with congestive heart failure
Timeframe: 10 years
Myocardial infarction
Timeframe: 2-year follow-up
Myocardial infarction
Timeframe: 5-year follow-up
Myocardial infarction
Timeframe: 10 years
Revascularization
Timeframe: 2-year follow-up
Revascularization
Timeframe: 5-year follow-up
Revascularization
Timeframe: 10-year follow-up
Incident Heart Failure
Timeframe: 2-year follow-up
Incident Heart Failure
Timeframe: 5-year follow-up
Incident Heart Failure
Timeframe: 10-year follow-up
Incident valvular disease
Timeframe: 2-year follow-up
Incident valvular disease
Timeframe: 5-year follow-up
Incident valvular disease
Timeframe: 10-year follow-up